Touchlight
At Touchlight we have developed a novel, synthetic DNA vector (dbDNA™) and enzymatic manufacturing process, which enables us to produce DNA at unprecedented speed, scale and purity. Using our patented enzymatic DNA production platform, we are supporting partners that are advancing genetic medicine.
Latest Content
Product News
Touchlight and GSK Sign License Agreement for Use of Enzymatic dbDNA Production Technology for mRNA Manufacturing
Touchlight, announced a license agreement with GSK. This agreement grants GSK non-exclusive rights to use Touchlight’s proprietary enzymatic dbDNA™ (doggybone DNA™) technology for the development and production of mRNA-based products.
Product News
Touchlight, Cell and Gene Therapy Catapult and Complement Therapeutics To Develop Innovative Manufacturing Process for Gene Therapies
The Cell and Gene Therapy Catapult (CGT Catapult), Touchlight, announce that they have been awarded over £1 million in a grant from Innovate UK, as part of the ‘Innovative Technologies: Nucleic Acid Medicines Manufacture’ competition.
Product News
University of Liverpool To Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical
The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.
Advertisement
